The DOI matches its OpenAlex record; 38 of the 38 references it cites were found in a registry or an index.
The Effect of Stroke and Stroke Prophylaxis With Aspirin or Warfarin on Quality of Life
Abstract
BACKGROUND: Because most strokes cause neurological impairment rather than death, stroke prophylaxis may improve quality of life more than length of life. Thus, an understanding of how stroke and stroke prophylaxis affect quality of life is central to clinical decision making for many patients. METHODS: We elicited quality-of-life estimates, known as utilities, for 3 degrees of severity of anticipated stroke-mild, moderate, and major- and for stroke prophylaxis with either warfarin sodium or aspirin therapy. We used the time tradeoff and standard gamble methods to elicit these utilities from 83 patients who had atrial fibrillation. RESULTS: Seventy patients completed the interview successfully. Their utilities for stroke ranged from worse than death (< 0) to as good as current health (1.0). The median utilities for mild, moderate, and major stroke were 0.94, 0.07, and 0.0, respectively. Although the median utilities decreased with increasing severity of stroke (P < .001), there was high interpatient variability within each degree of stroke severity. For example, 7 subjects (10%) rated a major stroke above 0.5, while 58 subjects (83%) rated it as equal to or worse than death. In contrast to the stroke utilities, the median utilities for warfarin and aspirin therapy were high-0.997 and 1.0, respectively. However, the interpatient variability for warfarin therapy was also important: 11 patients (16%) with atrial fibrillation rated the utility of warfarin therapy so low that their quality-adjusted life expectancy would be greater with aspirin. CONCLUSION: Patients' utilities for stroke prophylaxis and anticipated stroke vary substantially. Many patients view the quality of life with major stroke as tantamount to or worse than death. These findings highlight the relevance of incorporating patient preferences when choosing stroke prophylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
Measuring nominal scale agreement among many raters.
Fleiss, J. L. (1971) · Psychological Bulletin · doi:10.1037/h0031619 · Cited by 8,733
Utility approach to measuring health-related quality of life
Torrance, G. W. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90019-1 · Cited by 1,072
The Beaver Dam Health Outcomes study: Initial Catalog of Health-state Quality Factors
Fryback, D. G., Dasbach, E. J., Klein, R., Klein, B. E. K., Dorn, N., Peterson, K., & Martin, P. A. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300202 · Cited by 733
Interobserver agreement for the assessment of handicap in stroke patients.
Bamford, J. M., Sandercock, P. A., Warlow, C. P., & Slattery, J. (1989) · Stroke · doi:10.1161/01.str.20.6.828 · Cited by 693
Speech and Survival: Tradeoffs between Quality and Quantity of Life in Laryngeal Cancer
McNeil, B. J., Weichselbaum, R., & Pauker, S. G. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110223051704 · Cited by 677
The utility of different health states as perceived by the general public
Sackett, D. L., & Torrance, G. W. (1978) · Journal of Chronic Diseases · doi:10.1016/0021-9681(78)90072-3 · Cited by 668
Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.
Dennis, M. S., Burn, J. P., Sandercock, P. A., Bamford, J. M., Wade, D. T., & Warlow, C. P. (1993) · Stroke · doi:10.1161/01.str.24.6.796 · Cited by 567
Social preferences for health states: An empirical evaluation of three measurement techniques
Torrance, G. W. (1976) · Socio-Economic Planning Sciences · doi:10.1016/0038-0121(76)90036-7 · Cited by 524
A convenient approximation of life expectancy (the “DEALE”)
Beck, J. R., Pauker, S. G., Gottlieb, J. E., Klein, K., & Kassirer, J. P. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90787-2 · Cited by 469
Cited by
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Self-citationFuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L. E., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,348
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., & Singer, D. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022913 · Cited by 1,277
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J.-Y., Lowe, J. E., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.013 · Cited by 924
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J.-Y., Lowe, J. E., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214876d · Cited by 859
Gage, B. F., van Walraven, C., Pearce, L., Hart, R. G., Koudstaal, P. J., Boode, B. S. P., & Petersen, P. (2004) · Circulation · doi:10.1161/01.cir.0000145172.55640.93 · Cited by 749
Self-citationAntithrombotic Therapy in Atrial Fibrillation
Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., & Manning, W. J. (2008) · Chest · doi:10.1378/chest.08-0678 · Cited by 751
van Walraven, C., Hart, R. G., Singer, D. E., Laupacis, A., Connolly, S., Petersen, P., Koudstaal, P. J., Chang, Y., & Hellemons, B. (2002) · JAMA · doi:10.1001/jama.288.19.2441 · Cited by 714
Writing Committee Members, Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., et al. (2006) · Europace · doi:10.1093/europace/eul097 · Cited by 667
Eliciting public preferences for healthcare: a systematic review of techniques
Ryan, M., Scott, D. A., Reeves, C., Bate, A., van Teijlingen, E. R., Russell, E. M., Napper, M., & Robb, C. M. (2001) · Health Technology Assessment · doi:10.3310/hta5050 · Cited by 641
Antithrombotic Therapy in Atrial Fibrillation
Singer, D. E., Albers, G. W., Dalen, J. E., Go, A. S., Halperin, J. L., & Manning, W. J. (2004) · Chest · doi:10.1378/chest.126.3_suppl.429s · Cited by 547
Man-Son-Hing, M., Nichol, G., Lau, A., & Laupacis, A. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.7.677 · Cited by 538
(2001) · European Heart Journal · doi:10.1053/euhj.2001.2983 · Cited by 494
Prediction of Functional Outcome in Patients With Primary Intracerebral Hemorrhage: The FUNC Score
Rost, N. S., Smith, E. E., Chang, Y., Snider, R. W., Chanderraj, R., Schwab, K., FitzMaurice, E., Wendell, L., Goldstein, J. N., Greenberg, S. M., et al. (2008) · Stroke · doi:10.1161/strokeaha.107.512202 · Cited by 473
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.018 · Cited by 467
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
Freeman, J. V., Zhu, R. P., Owens, D. K., Garber, A. M., Hutton, D. W., Go, A. S., Wang, P. J., & Turakhia, M. P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00289 · Cited by 429
A review of the use of health status measures in economic evaluation.
Brazier, Deverill, Green, Harper, & Booth (1999) · Health Technology Assessment · doi:10.3310/hta3090 · Cited by 413
Utility assessment among patients with dry eye disease
Schiffman, R. M., Walt, J. G., Jacobsen, G., Doyle, J. J., Lebovics, G., & Sumner, W. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00462-7 · Cited by 366
Antithrombotic Therapy in Atrial Fibrillation
Albers, G. W., Dalen, J. E., Laupacis, A., Manning, W. J., Petersen, P., & Singer, D. E. (2001) · Chest · doi:10.1378/chest.119.1_suppl.194s · Cited by 360
Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
Shah, S. V., & Gage, B. F. (2011) · Circulation · doi:10.1161/circulationaha.110.985655 · Cited by 337
Self-citationMethods for the analysis of quality-of-life and survival data in health technology assessment.
Billingham, Abrams, & Jones (1999) · Health Technology Assessment · doi:10.3310/hta3100 · Cited by 307
Can Patients Be Anticoagulated After Intracerebral Hemorrhage?: A Decision Analysis
Eckman, M. H., Rosand, J., Knudsen, K. A., Singer, D. E., & Greenberg, S. M. (2003) · Stroke · doi:10.1161/01.str.0000078311.18928.16 · Cited by 304
Antithrombotic Therapy in Atrial Fibrillation
Laupacis, A., Albers, G., Dalen, J., Dunn, M. I., Jacobson, A. K., & Singer, D. E. (1998) · Chest · doi:10.1378/chest.114.5_supplement.579s · Cited by 294
Zhang, Y., Coello, P. A., Guyatt, G. H., Yepes-Nuñez, J. J., Akl, E. A., Hazlewood, G., Pardo-Hernandez, H., Etxeandia-Ikobaltzeta, I., Qaseem, A., Williams, J. W., et al. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.05.011 · Cited by 285
Eckman, M. H., Rosand, J., Greenberg, S. M., & Gage, B. F. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-2-200901200-00005 · Cited by 283
Self-citationFauchier, L., Hylek, E., Knight, E., Lane, D., Levi, M., Marin, F., Palareti, G., Collet, J.-P., Rubboli, A., Poli, D., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-10-0690 · Cited by 280
Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation
Eckman, M. H., Singer, D. E., Rosand, J., & Greenberg, S. M. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.958108 · Cited by 275
Man-Son-Hing, M. (1999) · JAMA · doi:10.1001/jama.282.8.737 · Cited by 271
Harrington, A. R., Armstrong, E. P., Nolan, P. E., & Malone, D. C. (2013) · Stroke · doi:10.1161/strokeaha.111.000402 · Cited by 259
Lees, K. R., Emberson, J., Blackwell, L., Bluhmki, E., Davis, S. M., Donnan, G. A., Grotta, J. C., Kaste, M., von Kummer, R., Lansberg, M. G., et al. (2016) · Stroke · doi:10.1161/strokeaha.116.013644 · Cited by 256
Patient Values and Preferences in Decision Making for Antithrombotic Therapy: A Systematic Review
MacLean, S., Mulla, S., Akl, E. A., Jankowski, M., Vandvik, P. O., Ebrahim, S., McLeod, S., Bhatnagar, N., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2290 · Cited by 253
Samsa, G. P., Reutter, R. A., Parmigiani, G., Ancukiewicz, M., Abrahamse, P., Lipscomb, J., & Matchar, D. B. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00151-6 · Cited by 140
“The resulting utilities were consistent with previously reported results [15,16] and also with unpublished utility data from a trial that recorded both Rankin score and quality of life using the Health Utility Index Mark 2 [17] for approximately 600 patients, at weeks 4 and 12 after stroke (Williams, G.”
ResultBossuyt, P., Stalmeier, P., Sprangers, M., van Dongen, C., Middeldorp, S., Bank, I., van der Meer, J., Hamulyák, K., Prins, M., & Locadia, M. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-02-0075 · Cited by 91
Lanitis, T., Leipold, R., Hamilton, M., Rublee, D., Quon, P., Browne, C., & Cohen, A. T. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.020 · Cited by 23
Coleman, C. I., Limone, B. L., Bookhart, B. K., Mody, S. H., & Nutescu, E. A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.02.006 · Cited by 18
“Direct costs from each complication were calculated from expected billing codes (using national average Medicare payment/ reimbursement rates without any adjustment) or from previously published studies [21–24].”
MethodResultQuon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1141780 · Cited by 12
Metadata
- Authors
- Gage, B. F.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association
- Published
- 1996-09-09
- Volume
- 156
- Issue
- 16
- Pages
- 1829-1829
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2066157763
- Cited by
- 370
- References
- 38
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.